ArcellxACLX
ACLX
About: Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Employees: 130
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
137% more call options, than puts
Call options by funds: $187M | Put options by funds: $78.7M
95% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 20
45% more capital invested
Capital invested by funds: $2.85B [Q2] → $4.13B (+$1.28B) [Q3]
11% more funds holding
Funds holding: 167 [Q2] → 186 (+19) [Q3]
6% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 62
4.51% less ownership
Funds ownership: 96.57% [Q2] → 92.06% (-4.51%) [Q3]
17% less funds holding in top 10
Funds holding in top 10: 12 [Q2] → 10 (-2) [Q3]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$100
32%
upside
Avg. target
$113
50%
upside
High target
$136
80%
upside
10 analyst ratings
10 positive
100%
0 neutral
0%
0 negative
0%
UBS Ashwani Verma 47% 1-year accuracy 8 / 17 met price target | 51%upside $114 | Buy Maintained | 10 Dec 2024 |
HC Wainwright & Co. Emily Bodnar 17% 1-year accuracy 26 / 150 met price target | 52%upside $115 | Buy Reiterated | 10 Dec 2024 |
Needham Gil Blum 21% 1-year accuracy 34 / 164 met price target | 39%upside $105 | Buy Reiterated | 10 Dec 2024 |
Truist Securities Asthika Goonewardene 20% 1-year accuracy 5 / 25 met price target | 80%upside $136 | Buy Maintained | 12 Nov 2024 |
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 52%upside $115 | Overweight Maintained | 8 Nov 2024 |
Financial journalist opinion
Based on 3 articles about ACLX published over the past 30 days
Positive
Investors Business Daily
1 week ago
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
Arcellx stock reversed lower Monday on positive results for its rival to Legend Biotech's multiple myeloma treatment, Carvykti. The post Arcellx And Legend Bio Trade Jabs In Multiple Myeloma.
Positive
Benzinga
1 week ago
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
On Sunday, Arcellx, Inc. ACLX revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM).
Neutral
Business Wire
1 week ago
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data will be presented during an oral presentation at the 66th American Society of.
Positive
Zacks Investment Research
1 month ago
Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice
Does Arcellx, Inc. (ACLX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Positive
Zacks Investment Research
1 month ago
Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?
Here is how Arcellx, Inc. (ACLX) and AbbVie (ABBV) have performed compared to their sector so far this year.
Negative
Zacks Investment Research
1 month ago
Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates
Arcellx, Inc. (ACLX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to loss of $0.81 per share a year ago.
Neutral
Business Wire
1 month ago
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. “We believe the data from the recently published ASH abstracts continues to differentiate anito-cel's clinical profile as a potentially best-in-class.
Positive
Zacks Investment Research
1 month ago
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Arcellx (ACLX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Neutral
Business Wire
1 month ago
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that it will present clinical data in a poster presentation from its Phase 1 study (abstract #4825) of anitocabtagene autoleucel (anito-cel) in patients with relapsed or refractory multiple myeloma (RRMM); preliminary clinical data in an oral presentation.
Positive
Seeking Alpha
3 months ago
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
Arcellx leverages proprietary platforms like D-Domain, ddCAR, and ARC-SparX to enhance immune response, targeting multiple myeloma, AML, MDS, and solid tumors. ACLX's lead therapy, anito-cel, shows strong clinical results in relapsed/refractory multiple myeloma, even for high-risk patients. Arcellx's strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million.
Charts implemented using Lightweight Charts™